Addressing the Challenges in Primary and Secondary Stroke Prevention

Slides:

Advertisements

Similar presentations

ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.

Advertisements

Silent No More:.

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

Atrial Fibrillation and PCI

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

NOACs In Long-term VTE Treatment: A State Of The Art Review

US Guidelines US Guidelines Low-risk Patients.

NOACs, AF, and PCI: What Do the Latest Data Suggest?

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Thrombosis, Cancer, and NOACs

Access to NOAC Therapy:

Appropriate Stroke Prevention Strategies in Atrial Fibrillation

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Emergency Management of NOAC Bleeding

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF

Up to Date on Which NOAC for Which Patient

REVERSAL AGENTS FOR NOACS: Do WE NEED THEM in THE EP LAB?

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Oral Anticoagulants in AFa,b A Brief History.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

The Essentials for Secondary Stroke Prevention

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

Efficacy and Safety of Edoxaban in Patients With AF and HF

Access to NOAC Therapy:

TAVR and the Risk of Thrombosis

Adherence in SPAF: Measures to Improve Care

What Anticoagulant Registries Are Revealing

Watching for the Patient With AF: Latest Advances and Technologies

Oral Anticoagulation in AF

Dos and Don’ts for High-Risk Elderly Patients With AF

Atrial Fibrillation.

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Taking the "Cryptogenic" Out of Cryptogenic Stroke

NOACs in AF: Consequences of Underdosing and NonAdherence

Anticoagulation and Thrombosis Management

Identifying High-Risk AF Patients

Factor Xa Inhibitors in PAD

A Time for Change for Managing Patients With VTE Who Have Cancer

What You Didn't Know About AF and Renal Dysfunction

Cancer-Associated Thrombosis

A Case Challenge.

New European Anticoagulant Approvals Will They Affect Practical Guidance?

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Managing Pulmonary Embolism Posthospital Discharge

NOAC Studies in VTE AF Studies Superior Outcomes.

Antithrombotics in Arterial Disease: Focus on Coronary Disease

Extraordinary Cases in VTE

Program Goals Background: Anticoagulation in Patients With VTE.

NOACs in AF: Consequences of Underdosing and NonAdherence

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Disease Burden of VTE Phases of VTE Treatment.

Taking the "Cryptogenic" Out of Cryptogenic Stroke

5 Good Minutes on Atrial Fibrillation-related Stroke

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Extraordinary Cases in Stroke Prevention

Antithrombotic Therapy in AF Patients Undergoing PCI

What's New in NOACs in AF?.

Treating Pulmonary Embolism Today

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

Addressing the Challenges in Primary and Secondary Stroke Prevention

Program Goals

AF Epidemiology[a]

AF-Related Stroke

Warfarin for Stroke Prevention in AF

NOAC SPAF Trials Meta-Analysis of 71,683 Patients

Antithrombotic Treatment by Stroke Risk: GLORIA-AF Registry

Modifiable Risk Factors for Bleeding in Patients With AF

2016 ESC Guidelines Stroke Prevention in AF

NOACs Reduce the Risk of ICH

Screening for AF

NOAC Trials for Stroke Prevention in AF: Baseline Characteristics

Nonadherence in AF

NOACs Reduce the Risk of All-Cause Mortality

Drug-Drug Interactions With NOACs

Anticoagulation After an ICH

NOAC Reversal Agents

Take-Home Messages

Abbreviations

Abbreviations (cont)